Orally Active Antischistosomal Early Leads Identified from the Open Access Malaria Box

Background:worldwide hundreds of millions of schistosomiasis patients rely on treatment with a single drug,praziquantel. therapeutic limitations and the threat of praziquantel resistance underline the need to discover and develop next generation drugs.methodology:we studied the antischistosomal properties of the medicines for malaria venture (mmv) malaria box containing 200 diverse drug-like and 200 probe-like compounds with confirmed in vitro activity against plasmodium falciparum. compounds were tested against schistosomula and adult schistosoma mansoni in vitro. based on in vitro performance,available pharmacokinetic profiles and toxicity data,selected compounds were investigated in vivo.principal findings:promising antischistosomal activity (ic50: 1.4-9.5 μm) was observed for 34 compounds against schistosomula. three compounds presented ic50 values between 0.8 and 1.3 μm against adult s. mansoni. two promising early leads were identified,namely a n,n′-diarylurea and a 2,3-dianilinoquinoxaline. treatment of s. mansoni infected mice with a single oral 400 mg/kg dose of these drugs resulted in significant worm burden reductions of 52.5% and 40.8%,respectively.conclusions/significance:the two candidates identified by investigating the mmv malaria box are characterized by good pharmacokinetic profiles,low cytotoxic potential and easy chemistry and therefore offer an excellent starting point for antischistosomal drug discovery and development. © 2014 ingram-sieber et al.